| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02905981 Details | 2020-09-22 Interventional | 2 | 1 | Citric Acid Sodium Citrate Anemia Anemia, Iron-De… Deficiency Dise… Iron Deficienci… Iron-Refractory… | Limited subjects, patient compliance Study terminated after one patient was enrolled. Patient discontinued due to lack of improvement in hemoglobin levels and subject compliance issues. Termination after only one subject enrolled does not allow definitive conclusions to be reached. | |||
| NCT02664922 Details | 2020-09-22 Interventional | 4 | 35 | Ketamine Propofol Remifentanil Sevoflurane Heart Diseases Cardiac Disease | Poor study design and too many study groups. - | |||
| NCT02188719 Details | 2020-09-22 Interventional | 1 | 15 | Acetaminophen Anti-Infective … Antilymphocyte … Diphenhydramine Everolimus Ganciclovir Liver Extracts Methylprednisol… Mycophenolic Ac… Prednisone Promethazine Tacrolimus Thymoglobulin Valganciclovir Liver Transplan… | The trial could not be completed within the grant timeline. Enrollment was terminated due to several factors:high number of ineligible subjects, slow enrollment, and manufacturing difficulties within the constraints of the funding period. | |||
| NCT04220476 Details | 2020-09-21 Interventional | 2 | 0 | Letrozole Palbociclib Breast Neoplasm… Breast Cancer | Initiating a new study with revised Statistics. - | |||
| NCT01916187 Details | 2020-09-21 Interventional | 1 | 0 | Imetelstat Motesanib dipho… Neuroblastoma | drug company withdrew support following re-examination of benefit-risk assessment for the
investigational use of imetelstat in this population - | |||
| NCT00894751 Details | 2020-09-21 Interventional | 1 | 98 | Dexmedetomidine Propofol Anesthesia Magnetic Resona… | low enrollment and high participant withdraw - | |||
| NCT00167661 Details | 2020-09-21 Interventional | 1/2 | 33 | Alemtuzumab Disorder Relate… | Enrollment suspended pending protocol revision to change study to observational - | |||
| NCT01915303 Details | 2020-09-18 Interventional | 2 | 68 | Cabergoline Pasireotide ACTH-Secreting … Pituitary ACTH … Cushings Diseas… | - - | |||
| NCT00539838 Details | 2020-09-17 Interventional | 3 | 33 | Azathioprine Immunosuppressi… Methotrexate Methylprednisol… Mycophenolic Ac… Ocrelizumab Prednisone Lupus Erythemat… Systemic Lupus … | The study was terminated prematurely when the decision was made that ocrelizumab was not likely
to benefit this patient population. The study was terminated before any patients reached the Week 48 visit. Therefore, the safety analysis included all safety data for the 33 randomized patients that were available up to the data cutoff date (22 March 2010) | |||
| NCT04334967 Details | 2020-09-16 Interventional | 4 | 13 | Ascorbic Acid Hydroxychloroqu… COVID-19 Coronavirus Inf… 2019 Novel Coro… 2019-nCoV Corona Virus In… SARS-CoV-2 | suspected unfavorable risk/benefit assessment - | |||
| NCT03116971 Details | 2020-09-16 Interventional | 1 | 2 | Etoposide Peposertib Lung Neoplasms Small Cell Lung… Small Cell Lung… | Enrollment in the study was prematurely terminated due to recruitment challenges and not due to
concerns of safety for the participants. - | |||
| NCT02436135 Details | 2020-09-16 Interventional | 1 | 10 | Idelalisib Polycythemia Polycythemia Ve… Primary Myelofi… Thrombocythemia… Thrombocytosis Myelofibrosis | - - | |||
| NCT04440488 Details | 2020-09-14 Interventional | 4 | 0 | Alpha 1-Antitry… Protease Inhibi… Alpha 1-Antitry… Emphysema Lung Diseases Lung Diseases, … Pulmonary Disea… Alpha1-antitryp… Chronic Obstruc… | Reevaluation of development strategy - | |||
| NCT04402580 Details | 2020-09-14 Interventional | 2 | 30 | Mycophenolic Ac… Rituximab Nephrosis Nephrotic Syndr… Syndrome Nephrotic Syndr… | due to unexpectedly high rate of relapse in the active comparator arm. - | |||
| NCT03038477 Details | 2020-09-14 Interventional | 2 | 0 | Durvalumab Pancreatic Canc… | Cancelled by PI - | |||
| NCT01466855 Details | 2020-09-14 Interventional | 1 | 36 | Topotecan Retinoblastoma | Competing studies - | |||
| NCT03959852 Details | 2020-09-11 Interventional | 4 | 6 | Fentanyl Ketamine Acute Pain Pain, Acute | Residency completed. - | |||
| NCT03382912 Details | 2020-09-11 Interventional | 2 | 52 | Nivolumab Carcinoma, Non-… Lung Neoplasms Non Small Cell … | The CYPRESS-2 trial was closed early after the planned final analysis because the risk benefit
ratio is unfavorable. - | |||
| NCT03298412 2016-003255-30 Details | 2020-09-11 Interventional | 2 | 10 | Blinatumomab Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Neoplasm, Resid… High-risk Diffu… | Early Closure due to rare patient population - | |||
| NCT00625898 Details | 2020-09-10 Interventional | 3 | 3509 | Bevacizumab Carboplatin Cyclophosphamid… Docetaxel Epirubicin Fluorouracil Trastuzumab Breast Neoplasm… Breast Cancer | - - |